Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Jun Liang
Jun Liang, South San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100292244 | HYDROXYLATED PYRIMIDYL CYCLOPENTANE AS AKT PROTEIN KINASE INHIBITOR - The present invention provides a compound and pharmaceutically acceptable salts thereof, comprising the Formula I. Also provided are methods of using the compound of this invention as an AKT protein kinase inhibitor and for the treatment of hyperproliferative diseases such as cancer. | 11-18-2010 |
| 20110065716 | HYDROXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer. | 03-17-2011 |
Jun Liang, Palo Alto, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20080280873 | Biaryl Substituted Pyrazinones as Sodium Channel Blockers - Biaryl substituted pyrazinone compounds represented by Formula I, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, urinary incontinence, itchiness, allergic dermatitis, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. | 11-13-2008 |
| 20080287457 | Inhibitors of Akt Activity - The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on. | 11-20-2008 |
| 20080318989 | Pyrimidine Kinase Inhibitors - The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula (I) wherein ring A, X, Y, Z, R | 12-25-2008 |
| 20100144732 | PYRIMIDINE KINASE INHIBITORS - The invention provides novel kinase inhibitors that are useful as therapeutic agents for example in the treatment malignancies where the compounds have the general formula I wherein Q, X, Y, Z, R | 06-10-2010 |
| 20100222321 | Inhibitors of akt activtiy - The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 09-02-2010 |
| 20100317643 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS - The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R | 12-16-2010 |
| 20110015204 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula (I), including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. | 01-20-2011 |
| 20110160221 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS - The present invention provides compounds of Formula I, including tautomers, resolved enantiomers, diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer. | 06-30-2011 |
Jun Liang, Dalian CN
| Patent application number | Description | Published |
|---|---|---|
| 20100162963 | Manila clam pedigree and breeding process thereof - A process for breeding a Manila clam pedigree, includes: directively breeding present Manila clam pedigrees having different shell shapes to obtain a shell shape pedigree (A) having best phenotypic character; directively breeding the shell shape pedigrees (A) from different geographical populations to obtain a geographical population pedigree (B) having best phenotypic character; directively breeding the geographical population pedigrees (B) having different shell colors to obtain a growth shell color pedigree (C) of fastest growth and a resistance shell color pedigrees (E) of highest stress resistance; hybridizing the growth shell color pedigree (C) and the resistance shell color pedigree (E) to obtain a first hybridied pedigree (F | 07-01-2010 |
| 20100162964 | Process for polycross breeding Manila clam pedigree - A process for polycross breeding a Manila clam pedigree, includes: providing present Manila clam pedigrees of different shell color types as parents; ecologically maturing the parents; reciprocally hybridizing the parents by every two of different shell color types to obtain offsprings thereof; nurturing the offsprings until gonads thereof mature synchronously; and hybridizing the matured offsprings with each other to obtain at least a four-way cross pedigree accumulating all valuable genes of the parents. | 07-01-2010 |
Jun Liang, Boyds, MD US
| Patent application number | Description | Published |
|---|---|---|
| 20110166061 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION - The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections. | 07-07-2011 |
Jun Liang, Shanghai CN
| Patent application number | Description | Published |
|---|---|---|
| 20110202669 | Method for Network Domain Name Resolution and the Resolution Device Thereof - The invention relates to a method for network domain name resolution, the domain name comprises a first portion domain name and a second portion domain name, and the resolution method comprising following steps: In a first network system, resolving the first portion domain name into a first network address; In the first network system, searching for a first network node corresponding to the first network address according to the resolved first network address; In a second network system, resolving the second portion domain name into a second network node address, and the domain name resolution system of the second network system being independent of the domain name resolution system of the first network system. As the resolution structure of the domain name in the Intranet is independent of the resolution structure of the domain name in the Internet, the IP address of the Intranet will not occupy the IP address resource of the Internet. | 08-18-2011 |